"biological-e"

One year on, the two Mobile Medical Units—clinics on wheels—have not just delivered treatment, they have delivered trust, dignity, and hope. In villages across the Shamirpet and Patancheru–Gaganpahad clusters, these vans are now recognised as a familiar sight, often welcomed with smiles and relief.

The nOPV2, which is the 10th pre-qualified vaccine of BE, is next-generation live, attenuated oral vaccine that significantly reduces the risk of circulating vaccine-derived Poliovirus type 2 (cVDPV2) outbreaks.

The study that was carried out among 250 healthcare workers and was published on December 14 in ‘Vaccines’

Hyderabad-based vaccine manufacturer Biological E. Limited (BE) on Friday announced that it has received approval from DCGI

The Hyderabad-based biopharma company, Biological E Limited, which has recently received approval for its Covid vaccine Corbevax

Hyderabad: Cementing Hyderabad’s position as Vaccine Capital of the World, Biological E (BE) has announced its expansion plans with an investment of more than Rs 1,800 crore. This will lead to a creation of employment to more than 2,500 people in its three facilities in Genome Valley. The expansion is primarily targeted to ramp up […]

Hyderabad: Biological E. Limited (BE), a Hyderabad-based vaccine and pharmaceutical company, has announced reduction in the price of its COVID-19 Vaccine Corbevax from Rs. 840 to Rs.250 a dose inclusive of GST, for Private COVID-19 vaccination centres. For the end user, the price would be Rs 400 a dose, including taxes and administration charges. The […]

Hyderabad: Vaccine maker Biological E Limited (BE) announced that it has been selected as a recipient of mRNA technology from the World Health Organisation (WHO) technology transfer hub. After examining a number of proposals from India, the World Health Organisation’s Advisory Committee on Vaccine Product Development (ACPDV) selected Biological E Limited as a recipient of […]

Hyderabad: Hyderabad-based vaccine maker Biological E Limited (BE) has priced its Corbevax, which has got approval for administration to adolescents aged 12 to 14 years, at Rs 800 (excluding GST) per dose for the private market, and Rs 145 per dose for the government, making it the cheapest vaccine in India and also globally, the […]

The data has been submitted by the company to the Subject Expert Committee for beneficiaries between 5-12 years of age, the sources told ANI.

Hyderabad: Covid outbreak was an unprecedented situation and when Biological E was called to act upon it and develop a vaccine, the focus was on making the vaccine effective, safe, and affordable as health budgets were severely constrained in many countries. Speaking at a panel discussion on the first day of BioAsia titled ‘Two years […]

Hyderabad: Biological E. Limited plans to complete production at a rate of 75 million doses of its COVID-19 vaccine Corbevax per month, anticipating over 100 million doses per month from February 2022 which will enable the city-based company to deliver 300 Million doses as promised to the Centre, BE said on Tuesday. Corbevax , India’s […]

The Centre must speed up negotiations with foreign companies towards the removal of stumbling blocks to expand coverage

Advanced arrangements made for 30 crore doses; Union Ministry of Health would be making an advance payment of Rs 1,500 crore to the Hyderabad company

CEPI will initially contribute up to $5 million towards the cost of scaling up the process for manufacturing the vaccine

The Ministry of External Affairs has made elaborate arrangements for the visit of the diplomats to the two manufacturing units at Medchal and Shamirpet.

Hyderabad-based vaccine firm will be responsible for evaluation and further development, including the commercialisation of the vaccine candidates

BE is making the vaccine in collaboration with Dynavax Technologies Corporation (Dynavax), a US-based vaccine focused biopharmaceutical company, and Baylor College of Medicine, a health sciences university in Houston.

The vaccine candidate includes an antigen in-licensed from BCM Ventures, Baylor College of Medicine’s integrated commercialisation team, along with Dynavax’s advanced adjuvant CpG 1018.